AD-5584 is a specific inhibitor of human acyl-CoA synthetase short chain family member 2 (ACSS2). It significantly reduces lipid storage, decreases colony formation, and increases cell death in vitro, while also confirming blood-brain barrier (BBB) permeability.

AD-5584 is a specific inhibitor of human acyl-CoA synthetase short chain family member 2 (ACSS2). It significantly reduces lipid storage, decreases colony formation, and increases cell death in vitro, while also confirming blood-brain barrier (BBB) permeability.

AD-5584 is a specific inhibitor of human acyl-CoA synthetase short chain family member 2 (ACSS2). It significantly reduces lipid storage, decreases colony formation, and increases cell death in vitro, while also confirming blood-brain barrier (BBB) permeability.

AD-5584 is a specific inhibitor of human acyl-CoA synthetase short chain family member 2 (ACSS2). It significantly reduces lipid storage, decreases colony formation, and increases cell death in vitro, while also confirming blood-brain barrier (BBB) permeability.

AD-8007 is a selective and brain-penetrant inhibitor of acetyl CoA synthase 2 (ACSS2). AD-8007 significantly reduces lipid storage, cell colony formation, acetyl-CoA levels and cell survival in vitro models, and increase tumor cell death, tumor burden and increases survival in in-vivo models. AD-8007 exhibits anti-cancer activity.

AD-8007 is a selective and brain-penetrant inhibitor of acetyl CoA synthase 2 (ACSS2). AD-8007 significantly reduces lipid storage, cell colony formation, acetyl-CoA levels and cell survival in vitro models, and increase tumor cell death, tumor burden and increases survival in in-vivo models. AD-8007 exhibits anti-cancer activity.

AD-8007 is a selective and brain-penetrant inhibitor of acetyl CoA synthase 2 (ACSS2). AD-8007 significantly reduces lipid storage, cell colony formation, acetyl-CoA levels and cell survival in vitro models, and increase tumor cell death, tumor burden and increases survival in in-vivo models. AD-8007 exhibits anti-cancer activity.

AD-8007 is a selective and brain-penetrant inhibitor of acetyl CoA synthase 2 (ACSS2). AD-8007 significantly reduces lipid storage, cell colony formation, acetyl-CoA levels and cell survival in vitro models, and increase tumor cell death, tumor burden and increases survival in in-vivo models. AD-8007 exhibits anti-cancer activity.

LTGO-33 is a potent and selective inhibitor of voltage-gated sodium channel NaV1.8. LTGO-33, with its potency in the nanomolar range, selectively inhibits NaV1.8 over 600 times more than human NaV1.1-NaV1.7 and NaV1.9. Its inhibition is not dependent on the state of the channels and displays consistent potency against both closed and inactivated conformations. LTGO-33 holds […]

LTGO-33 is a potent and selective inhibitor of voltage-gated sodium channel NaV1.8. LTGO-33, with its potency in the nanomolar range, selectively inhibits NaV1.8 over 600 times more than human NaV1.1-NaV1.7 and NaV1.9. Its inhibition is not dependent on the state of the channels and displays consistent potency against both closed and inactivated conformations. LTGO-33 holds […]